BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Cooperative Research Centre for Chronic Inflammatory Diseases 

University of Melbourne, Department of Medicine
The Royal Melbourne Hospital
Parkville  Victoria  3050  Australia
Phone: 03-8344-5480 Fax: 03-9347-1863


Core Participants:

Industry: AstraZeneca

University: The University of Melbourne; The University of Queensland; Monash University

Supporting Participants:

Industry: Zimmer Inc, IngenKo Pty Ltd

Research Focus

The CRC for Chronic Inflammatory Diseases was established in July 2001 to discover better treatments for serious chronic degenerative inflammatory diseases. These diseases include rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, atherosclerosis, and psoriasis, representing the greatest collective burden of suffering and economic cost in the developed world. In Australia alone, two of the largest inflammatory diseases, RA and COPD, which are the main focus of the CRC, cost the community in excess of $1 billion per annum.

Supplementary funding, commencing in July 2003, was obtained to apply our established macrophage biology discovery platform to develop new methods to treat joint disease. Osteoarthritis (OA) is a chronic degenerative joint disease that results in severe morbidity and often requires therapeutic joint replacement. Recent estimates are that 1.4 million people in Australia suffered from OA in 2000. By age 65, 16% of females and 10% of males have a disability due to arthritis. This puts an enormous burden on the community, costing $1.09 billion per annum, approximately 1.8% of the more that $60 billion of total health expenditure in Australia.

Our specific objectives are to:

    (i) discover new molecular targets involved in the pathogenesis of chronic inflammatory lung and joint disease and use this information to develop novel treatments for these disorders;

    (ii) reduce the burden of chronic inflammatory diseases;

    (iii) strengthen the Australian pharmaceutical/biotechnology sector.

    (iv) treat debilitating joint diseases by targeting the molecular processes that cause joint replacement failure, particularly in osteoarthritis;

    (v) generate synthetic tissues to repair injured joints.

Areas of Research Expertise

The original research program is centred on an unexploited therapeutic concept, the macrophage biology of chronic inflammatory disease, focusing on innovation in drug discovery and the application of emerging technologies, in particular gene microarrays, proteomics and genetically modified animal models of disease. This key theme has been extended through the addition of a fourth program, focused on a related disease, osteoarthritis, designed to investigate the reasons for failure of joint implants, believed to be caused by similar inflammatory processes. We predict that the phenotype of the macrophages and osteoclasts present in the inflamed tissue surrounding joint implants will be quite distinct from those found in other inflammatory lesions and will present distinct target genes for therapeutic intervention. As with RA and COPD, the study of failed joint implants provides insight into a wide range of related human pathologies. The same approaches and technologies as in our current Programs are being utilized to conserve resources and provide economies of scale. In addition, we have boosted our technology platform, supporting all four research programs, through the introduction of a fifth program involving new computational and structural biology techniques, which enable us to add substantial value to IP arising from our existing research.

Personnel involved in Centre

Postgraduate students: 21 PhD student positions
Full-time equivalent research staff: 70

Contact Details

Chair: Mr Robert Moses

Professor John Hamilton
Chief Executive Officer

Last Updated: 04-27-04

 Key Statistics

Ownership: Private

Web Site: CRC for Chronic Inflammatory Diseases

 Company News
Currently No News Articles